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Abstract: The consequences of mushroom poisoning range from mild, mostly gastrointestinal,
disturbances to organ failure or even death. This retrospective study describes presentations related
to mushroom poisoning at an emergency department in Bern (Switzerland) from January 2001 to
October 2017. Gastrointestinal disturbances were reported in 86% of the 51 cases. The National
Poisons Information Centre and mycologists were involved in 69% and 61% of the cases, respectively.
Identification of the mushroom type/family was possible in 43% of the cases. The most common
mushroom family was Boletaceae (n = 21) and the most common mushrooms Xerocomus chrysenteron
(n = 7; four being part of a cluster), Clitocybe nebularis, Lepista nuda and Lactarius semisanguifluus
(n = 5 each, four being part of a cluster). Poisonous mushrooms included Amanita phalloides (n = 3,
all analytically confirmed), Boletus satanas (n = 3), Amanita muscaria (n = 2) and Amanita pantherina
(n = 2). There were no fatalities and 80% of the patients were discharged within 24 h. Mushroom
poisoning does not appear to be a common reason for emergency consultation and most presentations
were of minor severity and related to edible species (e.g., due to incorrect processing). Nevertheless,
poisonous mushrooms and severe complications were also recorded. Collaboration with a poison
centre and/or mycologists is of great importance, especially in high risk cases.
Keywords: mushroom poisoning; mushroom toxicity; emergency department
1. Introduction
Of the estimated 5000 existing mushroom species, only 200–300 have been established to be safely
edible, while 50–100 are known to be poisonous to humans and the toxicity profile of most other species
has not been investigated [1,2]. Depending on the species, consumption of poisonous mushrooms can
cause various clinical signs and symptoms, ranging from mild, mostly gastrointestinal, disturbances
to organ failure and death [2–5]. Poisonous mushrooms contain a variety of different toxins whose
potency is influenced by many extrinsic and intrinsic factors present around the mushroom [6].
Main categories of mushroom toxins include protoplasmic poisons (result in generalized destruction
of cells, followed by organ failure), neurotoxins (which cause neurological symptoms such as coma,
convulsions and hallucinations), and gastrointestinal irritants (produce nausea, vomiting, abdominal
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cramping and diarrhoea) [6–8]. Patients with early symptoms (typically between thirty minutes and
six hours) often have a favorable outcome, while delayed symptoms (i.e., after six hours) are associated
with a higher risk of severe complications [3,8,9]. Although mushroom poisoning make up only a small
fraction of the total number of emergency consultations for poisoning [10], this poses an important
seasonal and regional problem for public health, with reported mortality rates of 8–12% [11,12] and
higher rates (up to 15–30%) with mushrooms containing amatoxin [1,2].
In Switzerland, the National Poisons Information Centre Tox Info Suisse provides 24-h medical
advice nationwide in cases of (suspected) poisoning. In recent decades, there has been a steady growth
in mushroom-related calls, with an autumnal peak seen each year [13]. In 2016, 446 (1.4%) of the 32063
documented consultations for poisoning were related to mushroom poisoning (56% in adults, 43% in
children and 1% of unknown age) [10]. The most commonly reported family was Boletaceae (6.3%),
while 34.9% of the mushrooms were self-harvested and not further identified [14]. In addition to the
medical advice offered by Tox Info Suisse, the Swiss Mushroom Control Association (Schweizerische
Vereinigung Amtlicher Pilzkontrollorgane, VAPKO) offers checkpoints for a voluntary assessment of
self-harvested mushrooms, in order to check edibility. In 2014, 4504 harvests were checked by the
French-speaking part of VAPKO; 37.9% of those contained inedible, 12.5% poisonous and 1.7% lethal
mushroom species [15].
Despite possible regional differences, only a study from the French speaking part of Switzerland
has investigated the epidemiology and clinical characteristics of patients presenting with mushroom
poisoning at an emergency department (ED) in Switzerland [3], and there are no data available from
the German speaking part of the country. The aim of this study was to describe the characteristics and
management of presentations related to mushroom poisoning at an emergency department in Bern,
Switzerland, during a 17 year period.
2. Materials and Methods
This was a retrospective single centre study of patients presenting at the ED of Bern University
Hospital (the Inselspital) with signs/symptoms related to mushroom exposure or intoxication during
a 17 year period (from 1 January 2001 to 31 October 2017). The ED of the Inselspital is both a
primary care facility (walk-in patients) and a tertiary referral centre for other hospitals in the region
and provides a catchment area for approximately two million people—with about 46,000 (2017)
emergencies admissions a year (≥16 years of age).
Patients admitted to the ED are registered in a specific clinical program: The program Qualicare
(Qualidoc, Trimbach, Switzerland) was used for the period from 1 January 2001 to 31 May 2012
and a second program—E.care (E.care BVBA, Turnhout, Belgium)—from 1 June 2012 to 31 October
2017. These databases were used to identify all patients presenting with (suspected) mushroom
poisoning. Cases were retrieved using a comprehensive full-text search algorithm with mushroom
poisoning, related terms and a large number of specific mushroom names, including their German
translation, as search terms. Each identified case was reviewed by one of the authors of the study.
We included each patient requiring medical evaluation at the ED for mushroom poisoning, regardless
of the circumstances of exposure (i.e., accidental or intentional) and the severity of the complaints.
We excluded patients with no history of mushroom consumption and cases where the complaints
could be clearly attributed to a cause other than mushroom poisoning based on the available final
diagnosis in the medical report and the documented evaluation of the physician assessing the patient.
The following parameters were extracted (if available) from the charts of included patients:
age, sex, type of transport to the ED (e.g., by ambulance), date of admission and discharge,
mushroom species and how they were obtained (e.g., self-harvest, purchased from commercial sources),
circumstances of exposure (e.g., accidental, recreational, suicide), symptoms, interval from ingestion
to onset of symptoms, laboratory findings (including detection of α-amanitin in urine), consultation
of a mycologist or Tox Info Suisse, treatment provided, type of discharge from the ED (e.g., inpatient
admission, outpatient therapy), length of hospital stay, and outcome (e.g., complications, death). As in
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previous studies [3,9], we differentiated between early onset of symptoms (i.e., within six hours of
ingestion) and delayed onset (i.e., >six hours). Furthermore, we distinguished between number of
“clusters” and number of “patients/cases” [16], i.e., patients admitted together at the ED because
they consumed the mushrooms jointly were regarded as one cluster, but each patient individually
as one patient/case. Data were analyzed descriptively; numerical data are presented as arithmetic
mean and standard deviation (SD) and nominal data as proportion (%). Detection of α-amanitin in
urine was performed at Zurich University Hospital using enzyme-linked immunoassay (ELISA) until
August 2016 and afterwards liquid chromatography- tandem mass spectrometry (LC-MS/MS) [17].
Data were analysed descriptively using Microsoft Excel (Microsoft, Redmond, WA, USA). The study
was approved by the local ethics committee (No. 2017-02243).
3. Results
During the study period (1 January 2001 to 31 October 2017), 62 patients were admitted to the
ED of Inselspital due to (suspected) mushroom poisoning. Eleven patients were excluded because
mushroom consumption could not be confirmed, or the complaints could clearly be attributed to a
cause other than mushroom poisoning. Finally, 51 patients were included in our study. The mean (±SD)
age of the study population was 48.4 ± 16.9 years (median 48 years), with a range from 15–79 years.
Twenty-nine patients (56.9%) were female and 22 (43.1%) male. The annual number of presentations
over the study period ranged from zero to ten patients, with a peak in 2008 (Figure 1). The seasonal
variation over the period of 17 years showed a peak in autumn (September, October; 27 patients, 52.9%)
and in summer (July, August; 13 patients, 25.5%) (Figure 2).
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Figure 1. Annual distribution of presentations due to mushroom poisoning (N = 51).
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Figure 2. Monthly distribution of presentations for mushroom poisoning (N = 51; bars represent the
sum of patients presenting during the same month throughout the study period).
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Table 1. Characteristics of cases presenting due to (suspected) mushroom poisoning, 2001–2017 (N = 51).
Patient ID Age(Years) Sex
Latency to
Onset of
Symptoms
Mushroom Species Type ofAcquisition
Consumed
Cooked or
Raw
Consultation
with a
Mycologist or
Tox Info Suisse
Symptoms/Signs,
and
Complications
Therapy
Abnormal Laboratory
Findings (on
Presentation, except
Mentioned Otherwise)
Length of
Hospital Stay and
Transfer to
Other Unit
1 62 M >12 h
Boletus edulis,
Macrolepiota procera,
Cantharellus cibarius
(not definitely
identified)
self-harvested not known both
diarrhoea,
abdominal pain,
vertigo, sweating
activated charcoal normal findings,alpha-amanitin negative
<24 h, discharged
from ED
2 15 W 6 h unknown self-harvested not known both nausea, vomiting
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin, penicillin G
sodium 128 mmol/L,
WBC 17.1 G/L,
alpha-amanitin negative
<24 h, discharged
from ED
3 22 M 6 h unknown self-harvested not known both nausea, vomiting,abdominal pain
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin, penicillin G
WBC 18.1 G/L,
alpha-amanitin negative
<24 h, discharged
from ED
4 48 M 5 h unknown self-harvested not known both
nausea, vomiting,
diarrhoea,
abdominal pain
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin, penicillin G
creatinine 106 µmol/L,
CRP 8 mg/L, bilirubin
total 27 µmol/L,
alpha-amanitin negative
<24 h, discharged
from ED
5 46 W 6 h unknown self-harvested not known both nausea, vomiting,abdominal pain
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin, penicillin G
WBC 17.1 G/L,
alpha-amanitin negative
<24 h, discharged
from ED
6 64 M 4 h Boletaceae edible commercialsources not known mycologist nausea, vomiting
intravenous fluids,
metoclopramide
ASAT 43 U/L, LDH 527
U/L, WBC 12.7 G/L
<24 h, discharged
from ED
7 60 W 4 h Boletaceae edible commercialsources not known mycologist nausea, vomiting
intravenous fluids,
meclizine/pyridoxine,
esomeprazole,
domperidone
unknown,
alpha-amanitin negative
<24 h, discharged
from ED
8 27 W 0.2 h unknown self-harvested cooked no
nausea, feeling of
faintness,
paraesthesia
no therapy unknown <24 h, dischargedfrom ED
9 36 W 4.5 h unknown commercialsources cooked Tox Info Suisse
nausea, vomiting,
diarrhoea,
abdominal pain
intravenous fluids,
metoclopramide,
butyl scopolamine
normal findings <24 h, dischargedfrom ED
10 34 W 2 h
Russula xerampelina
(not definitely
identified)
self-harvested not known Tox Info Suisse
nausea, vomiting,
diarrhoea,
abdominal pain
intravenous fluids,
paracetamol
ASAT 58 U/L, ALAT 85
U/L, AP 174 U/L, GGT
160 U/L, LDH 530 U/L,
CRP 48 mg/L ¶
<24 h, discharged
from ED
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Table 1. Cont.
Patient ID Age(Years) Sex
Latency to
Onset of
Symptoms
Mushroom Species Type ofAcquisition
Consumed
Cooked or
Raw
Consultation
with a
Mycologist or
Tox Info Suisse
Symptoms/Signs,
and
Complications
Therapy
Abnormal Laboratory
Findings (on
Presentation, except
Mentioned Otherwise)
Length of
Hospital Stay and
Transfer to
Other Unit
11 30 W >6 h Agaricus edible (notdefinitely identified)
commercial
sources not known no
nausea, vomiting,
abdominal pain,
hypaesthesia
intravenous fluids,
metoclopramide,
ondansetrone
normal findings <24 h, dischargedfrom ED
12 60 W 0.5 h unknown self-harvested not known mycologist nausea, abdominalpain, dry mouth
intravenous fluids,
activated charcoal,
silibinin
normal findings,
alpha-amanitin negative
<24 h, discharged
from ED
13 60 M 0.5 h unknown self-harvested not known mycologist nausea, abdominalpain, dry mouth
intravenous fluids,
activated charcoal,
silibinin
normal findings,
alpha-amanitin negative
<24 h, discharged
from ED
14∇ 67 W 12 h Amanita phalloides self-harvested not known both
prolonged nausea
and vomiting: on
the 4th day acute
renal failure,
macrohaematuria,
retinal
haemorrhages,
hemiplegia,
progressive
somnolence,
suspected
thrombotic
thrombocytopenic
purpura
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin,
metoclopramide
initially normal; on the
4th day increase in liver
enzymes (peak on the
6th day; ASAT 108 U/L,
ALAT 74 U/L) and
creatinine (peak on the
11th day; 398 µmol/L),
thrombocytopenia
(nadir of 23 G/L on the
9th day);
alpha-amanitin positive
792 h, internal
medicine,
abdominal surgery,
intensive unit care,
nephrology
15 42 M >12 h unknown self-harvested not known no nausea, diarrhoea no therapy unknown <24 h, dischargedfrom ED
16∇ 48 W >12 h unknown self-harvested cooked both
nausea, vomiting,
diarrhoea, vertigo,
fatigue
intravenous fluids,
silibinin
ASAT 43 U/L, ALAT 61
U/L, AP 106U/L, GGT
118 U/L, bilirubin total
22 µmol/L ¶,#
alpha-amanitin
urinalysis negative
84 h, internal
medicine
17 23 M 6 h
Amanita muscaria
(not definitely
identified)
commercial
sources not known Tox Info Suisse asymptomatic no therapy sodium 148 mmol/L
<24 h, discharged
from ED
18 70 W 0.2 h
Lepista nuda,
Hypholoma fasciculaea
or laterium
commercial
sources
(Lepista),
unknown
(Hypholoma)
not known both nausea, abdominalpain
intravenous fluids,
metoclopramide
bilirubin total 17
µmol/L
<24 h, discharged
from ED
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Table 1. Cont.
Patient ID Age(Years) Sex
Latency to
Onset of
Symptoms
Mushroom Species Type ofAcquisition
Consumed
Cooked or
Raw
Consultation
with a
Mycologist or
Tox Info Suisse
Symptoms/Signs,
and
Complications
Therapy
Abnormal Laboratory
Findings (on
Presentation, except
Mentioned Otherwise)
Length of
Hospital Stay and
Transfer to
Other Unit
19∇ 74 M 5.5 h Amanita phalloides self-harvested cooked both
nausea, vomiting,
diarrhoea, vertigo,
cramps
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin
ASAT 52 U/L, ALAT 42
U/L, GGT 68 U/L (peak
on the 6th day; 79 U/L),
creatinine 119 µmol/L,
glomerular filtration
rate (GFR) 52 mL/min,
CRP 7 mg/L, INR 3.8,
bilirubin total 17
µmol/L (peak on the
6th day; 38 µmol/L)„
alpha-amanitin positive
120 h, intensive
care
20 59 M 5 h unknown self-harvested cooked Tox Info Suisse
nausea, diarrhoea,
abdominal pain,
hallucinations
intravenous fluids
potassium 3.3 mmol/L,
CRP 7 mg/L,
alpha-amanitin negative
<24 h, discharged
from ED
21 47 W 2 h Boletus satanas self-harvested cooked Tox Info Suisse
nausea, vomiting,
diarrhoea,
abdominal pain,
headache, chills
intravenous fluids,
metoclopramide,
butylscopolamine,
esomeprazole
potassium 3.3 mmol/L <24 h, dischargedfrom ED
22 36 W 1.5 h Boletus satanas self-harvested raw both nausea, vomiting,diarrhoea
intravenous fluids,
activated charcoal,
metoclopramide
potassium 3.3 mmol/L <24 h, dischargedfrom ED
23 73 W n.a.
Clitocybe nebularis,
Xerocomus
chrysenteron, X.
badius, Lepista nuda,
Lactarius semisangui
fluus, Russula variata,
Amanita rubescens,
Laccaria amethystina,
Craterellus cornuco
pioides, Pseudohyd
num gelatinosum
self-harvested cooked both asymptomatic intravenous fluids,activated charcoal unknown
<24 h, discharged
from ED
24∇ 51 W 0.5 h same as patient ID23 self-harvested cooked both
nausea, diarrhoea,
thoracic pain
intravenous fluids,
activated charcoal
normal laboratory
findings 55 h, cardiology
25 71 M n.a. same as patient ID23 self-harvested cooked both asymptomatic
intravenous fluids,
activated charcoal unknown
<24 h, discharged
from ED
26 58 M n.a. same as patient ID23 self-harvested cooked both asymptomatic
intravenous fluids,
activated charcoal unknown
<24 h, discharged
from ED
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Table 1. Cont.
Patient ID Age(Years) Sex
Latency to
Onset of
Symptoms
Mushroom Species Type ofAcquisition
Consumed
Cooked or
Raw
Consultation
with a
Mycologist or
Tox Info Suisse
Symptoms/Signs,
and
Complications
Therapy
Abnormal Laboratory
Findings (on
Presentation, except
Mentioned Otherwise)
Length of
Hospital Stay and
Transfer to
Other Unit
27 71 M 0.4 h
Armillaria mellea,
Xerocomus
chrysenteron,
Chlorophyl lum
rachodes
self-harvested cooked both
nausea, vertigo,
fatigue, confusion,
sweating
intravenous fluids,
activated charcoal,
metoclopramide
ASAT 39 U/L, GGT 44
U/L, LDH 621 U/L,
INR 2.15
<24 h, discharged
from ED
28 69 W 0.4 h
Armillaria mellea,
Xerocomus
chrysenteron,
Chlorophyl lum
rachodes
self-harvested cooked both nausea, vomiting,vertigo
intravenous fluids,
activated charcoal,
metoclopramide
potassium 3.3 mmol/L, <24 h, dischargedfrom ED
29 33 W >12 h Clitocybe nebularis,Boletaceae self-harvested raw both
nausea, diarrhoea,
headache, dry
mouth
intravenous fluids,
activated charcoal,
silibinin
normal laboratory
findings
<24 h, discharged
from ED
30 49 W 6 h unknown commercialsources cooked Tox Info Suisse
nausea, vomiting,
diarrhoea,
abdominal pain
intravenous fluids,
metoclopramide
normal laboratory
findings
<24 h, discharged
from ED
31 73 W 1 h unknown self-harvested raw no nausea, vomiting,diarrhoea
intravenous fluids,
metoclopramide
LDH 513 U/L,
creatinine 95 µmol/L,
GFR 50 mL/min
<24 h, discharged
from ED
32 36 W >12 h unknown restaurantmeal cooked no
nausea, abdominal
pain
intravenous fluids,
metoclopramide
ALAT 102 U/L, GGT 90
U/L, bilirubin total 49
µmol/L
<24 h, discharged
from ED
33∇ 58 W 0.5 h unknown self-harvested raw Tox Info Suisse salivation
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin
GGT 95 U/L,
alpha-amanitin negative 72 h, intensive care
34∇ 79 M 4.5 h unknown self-harvested cooked both
nausea, vomiting,
vertigo,
unconsciousness
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin
potassium 5.7 mmol/L,
creatinine 88 µmol/L,
GFR 87 mL/min, WBC
11.9 G/L,
alpha-amanitin negative
120 h, intensive
care
35∇ 67 M >12 h Amanita phalloides self-harvested not known mycologist nausea, vomiting,diarrhoea
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin, gastric and
jejunal tube
CRP 30 mg/L, bilirubin
total 37 µmol/L, WBC
13.1 G/L, INR 1.3,
alpha-amanitin positive
216 h, intensive
care
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Table 1. Cont.
Patient ID Age(Years) Sex
Latency to
Onset of
Symptoms
Mushroom Species Type ofAcquisition
Consumed
Cooked or
Raw
Consultation
with a
Mycologist or
Tox Info Suisse
Symptoms/Signs,
and
Complications
Therapy
Abnormal Laboratory
Findings (on
Presentation, except
Mentioned Otherwise)
Length of
Hospital Stay and
Transfer to
Other Unit
36 53 W >6 h unknown self-harvested cooked Tox Info Suisse
nausea, vomiting,
diarrhoea, vertigo,
unconsciousness
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin
normal findings,
alpha-amanitin negative
<24 h, ward not
documented
37∇ 65 W 0.3 h
Mushrooms with
gills, Lactarius
semisanguifluus,
Boletaceae
self-harvested not known both
nausea, vomiting,
diarrhoea,
tachycardia,
sweating
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin
ASAT 41 U/L, ALAT 40
U/L, GGT 95 U/L, LDH
508 U/L, creatinine 79
mmol/L, GFR 68
mL/min, CRP 9 mg/L,
WBC 18.6 G/L,
haemoglobin 117 g/L,
alpha-amanitin negative
72 h,
gastroenterology
ward
38∇ 41 W 7 h unknown self-harvested not known Tox Info Suisse nausea, vomiting,paraesthesia
intravenous fluids,
activated charcoal,
N-acetylcysteine,
silibinin
normal findings 30 h, intensive careunit
39 30 W 4 h Macrolepiota procera self-harvested not known both
nausea, vomiting,
diarrhoea,
abdominal pain
intravenous fluids,
activated charcoal
normal findings,
alpha-amanitin negative
<24 h, discharged
from ED
40 54 M 0.8 h Amanita pantherina self-harvested cooked mycologist
nausea, vomiting,
abdominal pain,
fatigue, mild
visual
disturbances,
agitation,
psychological
excitation,
tachycardia
intravenous fluids,
activated charcoal
ASAT 40 U/L,
creatinine 104 µmol/L
<24 h, discharged
from ED
41 54 W 0.8 h Amanita pantherina self-harvested cooked mycologist
abdominal pain,
fatigue, agitation,
mild visual
disturbances
intravenous fluids,
activated charcoal normal findings
<24 h, discharged
from ED
42 19 M >12 h Psilocybe purchased onthe street raw no
vertigo, feeling of
faintness,
unconsciousness,
dyspnoea
intravenous fluids normal findings <24 h, dischargedfrom ED
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Table 1. Cont.
Patient ID Age(Years) Sex
Latency to
Onset of
Symptoms
Mushroom Species Type ofAcquisition
Consumed
Cooked or
Raw
Consultation
with a
Mycologist or
Tox Info Suisse
Symptoms/Signs,
and
Complications
Therapy
Abnormal Laboratory
Findings (on
Presentation, except
Mentioned Otherwise)
Length of
Hospital Stay and
Transfer to
Other Unit
43 46 M 0.3 h Boletus edulis (notdefinitely identified)
restaurant
meal cooked no
nausea, abdominal
pain
intravenous fluids,
metoclopramide normal findings
<24 h, discharged
from ED
44 53 W 7 h Boletus edulis (notdefinitely identified)
commercial
sources cooked no
nausea, diarrhoea,
headache, fever intravenous fluids normal findings
<24 h, discharged
from ED
45 43 W 3 h unknown self-harvested cooked both nausea, vomiting,diarrhoea
intravenous fluids,
activated charcoal,
metoclopramide
normal findings,
alpha-amanitin negative
<24 h, discharged
from ED
46 48 M 1 h unknown self-harvested cooked both nausea, vomiting,diarrhoea
intravenous fluids,
activated charcoal,
metoclopramide
GGT 52 U/L <24 h, dischargedfrom ED
47∇ 40 M 1.5 h Boletus satanas self-harvested raw both
nausea, vomiting,
diarrhoea,
tachycardia,
hypotension, fever,
suspected
disseminated
intravascular
coagulation (DIC)
intravenous fluids,
activated charcoal,
metoclopramide
ASAT 36 U/L, INR 1.32,
persistent
thrombocytopenia:
nadir on the 3th day
102 G/L
105 h, internal
medicine ward
48 24 M >12 h unknown self-harvested cooked Tox Info Suisse headache no therapy ASAT 38 U/L, ALAT126 U/L
<24 h, discharged
from ED
49 23 M 1 h
Amanita muscaria
(not definitely
identified)
purchased on
the street raw no
nausea, vomiting,
fatigue, aggression no therapy WBC 14.4 G/L
<24 h, discharged
from ED
50 28 W 4 h
Lycoperdales,
Xerocomus
chrysenteron
self-harvested raw both nausea, vomiting,diarrhoea, chills no therapy unknown
<24 h, discharged
from ED
51 26 M 1 h
unknown
psycho-active
mushrooms
purchased on
the street raw Tox Info Suisse
nausea, vomiting,
extrapyramidal
symptoms, panic,
sweating
no therapy unknown <24 h, dischargedfrom ED
∇ Hospitalisation > 24 h; ¶ Liver enzymes and cholestasis parameters elevated prior to mushroom exposure; # Laboratory findings during the rest of the hospitalisation not available; n.a.:
not applicable; W: woman; M: man; Reference range: aspartate aminotransferase (ASAT) <35 U/L; alanine aminotransferase (ALAT) <35 U/L, alkaline phosphatase (AP) 35–104 U/L;
gamma-glutamyl transpeptidase (GGT) <40 U/L; bilirubin total <17 µmol/L; lactate dehydrogenase (LDH) <480 U/L; C-reactive protein (CRP) <5 mg/L; haemoglobin 135–168 g/L; white
blood cell (WBC) 3.00–10.5 G/L; international normalised ratio (INR) 0.7–1.2; sodium 132–146 mmol/L, potassium 3.5–4.5 mmol/L.
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Table 1 shows the characteristics of the included cases. Forty patients (78.4%) were treated as
outpatients and stayed at the ED for less than 24 h. One patient (ID 36) was admitted as inpatient (ward
not documented), but was discharged within the first 24 h, and ten patients (19.6%) were hospitalised
for more than 24 h (Table 1). In 58.8% (n = 30) of the cases, transport to the ED was organised by the
patients themselves, 19.6% (n = 10) by another hospital and the remaining 21.6% (n = 11) by general
practitioners, the police, Tox Info Suisse, air rescue service or internal allocation. Mycologists were
involved in 60.8% (n = 31) of the cases and Tox Info Suisse was contacted for 35 patients (68.6%) (Table 1).
The exact identification of the mushroom type was possible in 37.3% (n = 19) of the cases. In 13.7%
(n = 7), the mushroom species were not definitely identified, in 5.9% (n = 3) only the mushroom family
could be determined and in 43.1% (n = 22) the mushroom type remained unspecified/unknown. Table 2
shows the family of the identified and not definitely identified mushrooms, including information
about their potential toxicity and other current names [18–28], as well as the reported symptoms and
signs and their onset latency in our study.
Table 2. Family [18–28], symptoms/signs and interval from ingestion to symptoms of identified and
not definitely identified mushrooms (n = number of cases; more than one mushroom involved in
some cases).
Family Species n Comment Symptoms and Signs
Interval from
Ingestion to
Symptoms
Agaricaceae
(n = 5)
Agaricus
bisporus 1
Edible (in Switzerland
sold only from cultivated
mycelium)
nausea, vomiting, abdominal pain,
hypesthesia >6 h
Chlorophyllum
rachodes 2 Edible (in Switzerland)
nausea, vomiting, vertigo,
confusion, sweating, fatigue 0.4 h
Macrolepiota
procera 2 Edible
nausea, vomiting, diarrhea,
abdominal pain, vertigo, sweating 4–>12 h
Amanitaceae
(n = 11)
Amanita
muscaria 2 Poisonous
nausea, vomiting, aggression,
fatigue 1–6 h
Amanita
pantherina 2 Poisonous
nausea, vomiting, abdominal pain,
agitation, psychological excitation,
visual disturbances, tachycardia,
fatigue
0.75 h
Amanita
phalloides 3 Poisonous
nausea, vomiting, diarrhea,
vertigo, cramps, hemiplegia,
somnolence, acute renal failure,
macroheamaturia, retinal
hemorrhages, thrombotic
thrombocytopenic purpura
5.5–>12 h
Amanita
rubescens 4 Edible
nausea, diarrhea, thoracic pain,
asymptomatic 0.5 h
Boletaceae
(n = 21)
n.a. 4
Not further identified
Edible, non-edible,
poisonous depending on
the species
nausea, vomiting, diarrhea,
headache, dry mouth, sweating,
tachycardia
0.3–>12 h
Boletus edulis 3 Edible nausea, diarrhea, abdominal pain,vertigo, sweating, headache, fever 0.3–>12 h
Boletus satanas 3
Poisonous
Current name:
Rubroboletus satanas
nausea, vomiting, diarrhea,
abdominal pain, headache,
tachycardia, hypotension, chills,
fever, suspected DIC
1.5–2 h
Xerocomus
chrysenteron 7
Edible
Current name:
Xerocomellus chrysenteron
nausea, vomiting, diarrhea,
vertigo, confusion, sweating,
thoracic pain, fatigue, chills,
asymptomatic
0.4–4 h
Xerocomus
badius 4
Edible
Current name: Imleria
badia
nausea, diarrhea, thoracic pain,
asymptomatic 0.5 h
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Table 2. Cont.
Family Species n Comment Symptoms and Signs
Interval from
Ingestion to
Symptoms
Cantharellaceae
(n = 5)
Cantharellus
cibarius 1 Edible
diarrhea, abdominal pain, vertigo,
sweating >12 h
Craterellus
cornucopioides 4 Edible
nausea, diarrhea, thoracic pain,
asymptomatic 0.5 h
Hydnangiaceae
(n = 4)
Laccaria
amethystina 4 Edible
nausea, diarrhea, thoracic pain,
asymptomatic 0.5 h
Incertae sedis
(n = 4)
Pseudohydnum
gelatinosum 4 Edible
nausea, diarrhea, thoracic pain,
asymptomatic 0.5 h
Physalacriaceae
(n = 2)
Armillaria
mellea 2
Edible but has to be
pre-cooked in boiling
water
nausea, vomiting, vertigo,
confusion, sweating, fatigue 0.4 h
Russulaceae
(n = 10)
Russula variata 4
Edible
Current name: Russula
cyanoxantha
nausea, diarrhea, thoracic pain,
asymptomatic 0.5 h
Russula
xerampelina 1 Edible
nausea, vomiting, diarrhea,
abdominal pain 2 h
Lactarius
semisanguifluus 5 Edible
nausea, vomiting, diarrhea,
sweating, thoracic pain,
tachycardia, asymptomatic
0.3–0.5 h
Strophariaceae
(n = 1)
Hypholoma
fasciculaea or
laterium
1 Poisonous nausea, abdominal pain 0.2 h
Tricholomataceae
(n = 10)
Clitocybe
nebularis 5
Edible in Switzerland but
has to be prepared in
boiling water
Considered non-edible in
Germany
nausea, diarrhea, headache, dry
mouth, thoracic pain,
asymptomatic
0.5–>12 h
Lepista nuda 5 Edible nausea, abdominal pain, diarrhea,thoracic pain, asymptomatic 0.2–0.5 h
n.a. Lycoperdales 1 Outdated orderEdible and non-edible nausea, vomiting, diarrhea, chills 4 h
n.a.: not applicable.
In 74.5% of the cases (n = 38), the mushrooms were self-harvested and in 94.1% of the cases (n = 48)
exposure was accidental. Intentional ingestion included recreational use in two cases (ID 17, 49) and
a suicide attempt in one case (ID 33, ingestion of unspecified mushrooms and arum; negative urine
analysis for α-amanitin). In most cases, the symptoms of mushroom poisoning were gastrointestinal
disturbances; further reported symptoms included neurological, psychiatric, and cardiovascular
disorders (Table 3).
Table 3. Clinical characteristics of mushroom poisoning (N = 51).
n (%)
Gastrointestinal 44 (86.3)
nausea 42 (82.4)
vomiting 30 (58.8)
diarrhoea 23 (45.1)
abdominal pain 18 (35.3)
Neurological/Psychiatric 23 (45.1)
vertigo 8 (15.7)
agitation/aggression/panic/psychological excitation 5 (9.8)
headache 4 (7.8)
paraesthesia/hypaesthesia 3 (5.9)
unconsciousness 3 (5.9)
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Table 3. Cont.
n (%)
feeling of faintness 2 (3.9)
mild visual disturbances 2 (3.9)
confusion 1 (2)
extrapyramidal symptoms 1 (2)
hemiplegia 1 (2)
spasms 1 (2)
hallucinations 1 (2)
cholinergic symptoms (e.g., sweating, salivation) 5 (9.8)
anticholinergic symptoms (e.g., dry mouth) 3 (5.9)
Cardiovascular 5 (9.8)
tachycardia 3 (5.9)
thoracic pain 1 (2)
hypotension 1 (2)
dyspnoea 1 (2)
Miscellaneous/other 10 (19.6)
fatigue 5 (9.8)
chills/fever 4 (7.8)
renal failure 1 (2)
(suspected) thrombotic thrombocytopenic purpura 1 (2)
(suspected) disseminated intravascular coagulation (DIC) 1 (2)
Among the 48 symptomatic patients (94.1%), 35 patients (68.6%) presented with early symptoms
(i.e., within the first six hours) and 13 patients (25.5%) with delayed symptoms (i.e., start more than six
hours post-ingestion) (Figure 3).
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(hospitalisation period: five to 33 days). One of these patients (ID 14), developed acute renal failure
on the 4th day and elevated liver enzymes with a peak on the 6th day (max. ASAT 108 U/L, ALAT
74 U/L), despite normal laboratory parameters during the first three days (Table 1). The acute renal
failure and elevation of the liver enzymes were followed by thrombocytopenia, macrohaematuria,
retinal hemorrhage, left side hemiplegia and progressive somnolence. Thrombotic thrombocytopenic
purpura due to mushroom intoxication was suspected. After 33 days, the patient was discharged
from hospital; no liver or kidney transplantation were needed. Other severe complications included
disseminated intravascular coagulation (DIC) and persistent thrombocytopenia in one case (ID 47)
after ingestion of Boletus satanas (Table 1). After four days, the patient was discharged from hospital
with no subsequent complications. Furthermore, unconsciousness was reported by three patients
(ID 34,36,42) (Tables 1 and 3).
In 84.3% of the cases (43 patients), treatment included intravenous fluids (i.e., sodium chloride
0.9%). Symptomatic therapy included metoclopramide (16 patients, 31.4%), butylscopolamine
(two patients, 3.9%), meclozine/pyridoxine, domperidone, ondansetron, esomeprazole and
paracetamol (one case each, 2%). Twenty-nine patients received activated charcoal (56.9%); 16 patients
(31%; ID 2–5,13–15,17,20,32,38–49) were treated with silibinin, 12 patients (24%; ID 2–5,15,20,38–49)
with N-acetylcysteine, and four (8%, ID 2–5) with penicillin G. Seven patients received no treatment,
either because they were asymptomatic, or due to spontaneous resolution of their symptoms.
Gastric and jejunal tubes were used in one case due to prolonged diarrhoea and vomiting (Table 1).
All patients had favorable outcomes and there were no cases of death or liver failure. Only one patient
(ID 14), developed renal failure, but could be discharged from hospital after 33 days without further
complications. Table 4 shows the group-intoxications recorded during the study period (14 clusters).
Table 4. Cases of group intoxication (clusters).
Cluster Size
(Number of Persons
Involved)
Patient ID Mushroom Species Symptoms and Signs
Interval from
Ingestion to
Symptoms
Comment
4 2–5 unknown
nausea (n = 4), vomiting (n = 4),
abdominal pain (n = 3), diarrhoea
(n = 1)
5–6 h
2 6–7 Boletaceae nausea (n = 2), vomiting (n = 2) 4 h
2 12–13 unknown nausea (n = 2), abdominal pain (n = 2),dry mouth (n = 2) 0.5 h
2 14 Amanita phalloides
nausea (n = 1), vomiting (n = 1), acute
renal failure (n = 1), macrohaematuria
(n = 1), retinal haemorrhages (n = 1),
hemiplegia (n = 1), progressive
somnolence, (n = 1), suspected
thrombotic thrombocytopenic
purpura (n = 1)
12 h
Only one patient of
this cluster
consulted our ED
2 16, 48 unknown
nausea (n = 1), vomiting (n = 1),
diarrhoea (n = 1), fatigue (n = 1),
vertigo (n = 1), headache (n = 1)
>12 h
2 21 Boletus satanas
nausea (n = 1), vomiting (n = 1),
abdominal pain (n = 1), diarrhoea
(n = 1), chills (n = 1), headache (n = 1)
2 h
Only one patient of
this cluster
consulted our ED
3 22, 47 Boletus satanas
nausea (n = 2), vomiting (n = 2),
diarrhoea (n = 2), fever (n = 1),
tachycardia (n = 1), hypotension
(n = 1), suspected DIC (n = 1)
1.5 h
Only two patients
of this cluster
consulted our ED
4 23–26
Xerocomus chrysenteron,
X. badius, Lepista nuda,
Clitocybe nebularis,
Lactarius semisanguifluus,
Russula variata, Amanita
rubescens, Laccaria
amethystina, Craterellus
cornucopioides,
Pseudohydnum
gelatinosum
nausea (n = 1), diarrhoea (n = 1),
thoracic pain (n = 1) 0.5 h
Only one patient
had symptoms, the
other three were
asymptomatic
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Table 4. Cont.
Cluster Size
(Number of Persons
Involved)
Patient ID Mushroom Species Symptoms and Signs
Interval from
Ingestion to
Symptoms
Comment
2 27, 28
Xerocomus chrysenteron,
Chlorophyllum rachodes,
Armillaria mellea
nausea (n = 2), vertigo (n = 2),
vomiting (n = 1), sweating (n = 1),
fatigue (n = 1), confusion (n = 1)
0.4 h
2 35 Amanita phalloides nausea (n = 1), vomiting (n = 1),diarrhoea (n = 1) >12 h
Only one patient of
this cluster
consulted our ED
2 37
Mushrooms with gills,
Lactarius semisanguifluus,
Boletaceae
nausea (n = 1), vomiting (n = 1),
diarrhoea (n = 1), sweating (n = 1),
tachycardia (n = 1)
0.3 h
Only one patient of
this cluster
consulted our ED
4 40, 41 Amanita pantherina
abdominal pain (n = 2), fatigue (n = 2),
agitation (=2), mild visual
disturbances (n = 2), nausea (n = 1),
vomiting (n = 1), psychological
excitation (n = 1), tachycardia (n = 1)
0.8 h
Two patients of
this cluster visited
another ED
3 45, 46 unknown nausea (n = 2), vomiting (n = 2),diarrhoea (n = 2) 1–3 h
Only two patients
of this cluster
consulted our ED
3 50 Lycoperdales, Xerocomuschrysenteron
nausea (n = 2), vomiting (n = 2),
diarrhoea (n = 2), chills (n = 1),
asymptomatic (n = 1)
4–12 h
Only one patient of
this cluster
consulted our ED
Although the total number of cluster patients was 37, data were not available for ten of those
patients who did not consult our ED. Therefore, 27 of the cluster patients are described in our study
(Table 1; ID 2–7,12–14,16,21–28,35,37,40,41,45–48,50).
4. Discussion
During the study period of 17 years, 51 cases related to mushroom poisoning presented in the ED,
with a seasonal peak in autumn and 27 cases as part of a cluster (14 clusters, with only one or some of
the persons involved consulting our ED in some cases). In three quarters of the cases, the mushrooms
were self-harvested. A mycologist and/or Tox Info Suisse were involved in the majority of the cases,
and the exact mushroom type or family could be identified in almost half of the cases. In the majority
of the cases, the symptoms were gastrointestinal disturbances of minor severity, and the patients were
discharged within 24 h after symptomatic therapy was provided. Although there were no cases of
death or liver failure, there were three cases of analytically confirmed Amanita phalloides poisoning,
and, in one case, acute renal failure, thrombotic thrombocytopenic purpura with retinal haemorrhages
and left side hemiplegia as complications. Other severe complications included a case of DIC after
ingestion of Boletus satanas.
Boletaceae was the most commonly identified mushroom family in our study, as in the report from
Tox Info Suisse [10] and the study from the French part of Switzerland [3], which might indicate that this
mushroom is commonly consumed in Switzerland. As in previous studies [2,29], most presentations
were related to edible species, which is probably associated with incorrect handling during collection,
transport and storage of these mushrooms (e.g., collection in plastic bags, long period of transport at
high temperature, long-term storage of mushroom dishes) [29]. Cases with poisonous and potentially
life-threatening species were less common and included Amanita phalloides, Boletus satanas, Amanita
muscaria and Amanita pantherina. Among the main mushroom toxins categories, gastrointestinal
irritants were the most common in our study, followed by neurotoxins and protoplasmic poisons.
A check list of some important points regarding patient history and management in cases of
(suspected) mushroom poisoning is contained in the supplement (Table A1, data from [30–34]).
Although not routinely available, analytical methods such as urinary ELISA can be used to
detect amatoxin in cases of suspected amatoxin poisoning. This method has good sensitivity (up to
100%), especially if performed within 36 h after ingestion [35,36], although the amatoxin-level does not
correlate with the disease severity [37]. In our study, urine was tested for α-amanitin in more than one
third of the cases. Of these, the great majority were negative, which might be because of the ingestion
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of species lacking amatoxin or because the test was performed in the first six hours after ingestion,
since detection in urine is only reliable after six hours post-ingestion [36,37], or too late after the meal.
The characteristic sequence of the amatoxin-toxidrome with hepatic and multisystem organ failure
typically appearing two to six days after mushroom consumption [1,8] was seen in one of the patients
in our study with analytically confirmed Amanita phalloides poisoning (Table 1, ID 14), who developed
nausea and vomiting after a latency of 12 h and liver and kidney function deterioration on the fourth
day and after apparent clinical improvement. Coagulopathy, as also seen in this case in our study,
is also reported as possible complication in this stage, which spans four to seven days [1]. The other
two patients in our study with analytically confirmed Amanita phalloides poisoning developed none
(ID 35) or only moderate (ID 19) transaminase elevation. Despite this, those patients were hospitalised
for several days, most probably to assure regular follow-ups in order to exclude a delay onset hepatic
and/or multisystem organ failure.
Treatment of Amanita phalloides poisoning includes administration of activated charcoal for
gastrointestinal decontamination and silibinin [37], a milk thistle extract that has been shown to
inhibit amatoxin uptake by the OATP1B3 transporters located in hepatocyte membranes [1,38,39]
and to lower mortality in cases of amatoxin poisoning [40]. The combination of penicillin G and
silibinin is not recommended, since it seems to worsen outcome compared to silibinin alone [41].
In case of hepatotoxicity, recommendations also include administration of N-acetylcysteine, similarly
to paracetamol intoxication [37,40]. In our study, all three patients with Amanita phalloides ingestion
received activated charcoal, silibinin and N-acetylcysteine. Despite the current recommendation,
penicillin G was administered in combination with silibinin in four cases in our study, which might
be because older guidelines were applied (all four cases with penicillin G administration were from
2001). Furthermore, since some patients with suspected poisoning received silibinin as precautionary
measure while awaiting the analytical results, an in-house test could contribute to avoiding unnecessary
administration of drugs and reducing length of hospital stay.
Similarly to other studies [3,4,29], in the majority of our cases the symptoms began with a latency
of less than six hours, which is usually associated with a favourable outcome, since mushrooms
that only cause acute toxicity are rarely life-threatening [3,8,9]. However, early symptoms do not
exclude ingestion of potentially dangerous mushrooms, since patients often ingest more than one
type of mushroom and even amatoxin-containing mushrooms can (rarely) cause symptoms before
six hours [31,34]. This is also represented in our findings, as one of three patients with analytically
confirmed amatoxin poisoning presented with a latency of less than 6 h (Table 1, ID 19). In case of
amatoxin-containing mushroom poisoning, earlier onset of gastroenteritis after consumption may
correlate with more severe hepatotoxicity [42].
Identification of the specific mushroom(s) involved can contribute to appropriate diagnostic and
treatment. In cases of mushroom poisoning, the exact mushroom species is successfully identified
in the range of 5–27% of patients [3,31], with only one study [16] reporting higher rates of almost
90%. In our study, we were able to identify the exact mushroom type or family in almost half of the
cases, a rate higher than most of the reported rates in the literature, most probably due to the close
contact between the Inselspital and Tox Info Suisse/mycologists. The authors of the study in Italy [16]
also report that the high identification rate was due to the available mycologist service in cases of
suspected mushroom poisoning, while, in the study from the French speaking part of Switzerland [3],
a mycologist was contacted in only one third of the cases. These findings highlight the importance of
collaboration between EDs and the local poison control centres and/or mycologists, in order to enable
mushroom identification and professional consultation, especially in cases of high risk.
Similarly to our findings, analysis of mushroom poisoning data from Tox Info Suisse also shows
marked seasonal fluctuation [2] and most published cases of mushroom poisoning are recorded in the
autumn (September and October) and late summer (July and August) [2,3,11,13,16,29]. This autumnal
peak is most probably associated with the levels of rainfall, temperature and humidity during this
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period in Switzerland, which facilitates the growth of mushrooms and is also part of the wild mushroom
season (May–October) [2].
The limitations of our study include the retrospective design. Although we aimed to identify all
mushroom poisoning cases during the study period using the extensive search of our emergency unit
specific software, it is possible that some cases were missed, e.g., if a patient was falsely diagnosed or
did not mention the mushroom consumption, or that in some cases the symptoms were attributable to
another cause that remained unrecognized despite thorough diagnostic at the ED. Moreover, although
it is to assume that the patients remained free of symptoms if there was no re-presentation following
their discharge, no information was available regarding their further outcome after leaving the ED.
It is also possible that in some cases the treatment did not contribute to the clinical improvement (e.g.,
when administered as precautionary measure while awaiting the analytical results). Thus, it is not
possible to provide an accurate evaluation of the undertaken therapeutic measures, Furthermore, it is
possible that the diagnosis of mushroom poisoning was made after discharge from the ED or that
patients from peripheral hospitals were directly admitted to a ward, thus resulting in cases that could
not be found in our ED database, and it is also possible that some patients developed symptoms or
complications after being discharged. Moreover, we cannot report in how many cases identification or
exclusion of amatoxin-containing mushrooms was provided by the Tox Info Suisse/mycologist before
the analytical results were available, since the exact time a mushroom specialist was contacted is not
known. As a result, it is also not possible to describe how the patient management was adjusted (e.g.,
stopped or intensified) based on the mushroom specialist consultation in each case. Finally, our data
may not be generalised to other regions in Switzerland, inter alia due to differences in local weather.
The main strengths of our study include its long duration of 17 years. In addition, we frequently
consulted a mycologist and Tox Info Suisse and this contributed to our high rate of identification of
the mushrooms.
5. Conclusions
Based on our findings, ED consultations due to mushroom poisoning do not seem to be very
common and mostly include mild symptoms associated with gastrointestinal irritants, usually with
favorable outcome. However, although less common, cases of poisonings with potential lethal
mushrooms and severe complications were also recorded. Collaboration with the local poison centre
and a mycologist is of great importance for the identification of the mushroom(s) involved and
decisions on patient management, especially in cases of high risk. The data of our study can contribute
to the development of preventive strategies, such as medical personnel training and information
material for the public (e.g., using websites or other media) on the correct handling of and potentially
life-threatening mushrooms, especially during the high risk season for mushroom poisoning.
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Abbreviations
ALAT alanine aminotransferase
AP alkaline phosphatase
ASAT aspartate aminotransferase
CRP C-reactive protein
DIC disseminated intravascular coagulation
ED emergency department
ELISA enzyme-linked immunoassay
GFR glomerular filtration rate
GGT gamma-glutamyl transpeptidase
h hour(s)
INR international normalized ratio
LC-MS/MS liquid chromatography-tandem mass spectrometry
LDH lactate dehydrogenase
M man
n.a. not applicable
OATP organic anion transporting polypeptides
SD standard deviation
W woman
WBC white blood cell
Appendix A
Table A1. Checklist of management in cases of (suspected) mushroom poisoning (data from [30–34]).
Questions/Measures Comments
Patient history
Where were the mushrooms
collected?
Many toxic mushrooms tend to grow in woodlands;
growing season and geographic variation may help
identify particular mushrooms.
What type of tree was the
mushroom near/on? Amanita phalloides may grow under/near oak or pine trees.
More than one type of mushroom
collected?
What did the mushroom look like? Description might suggest potential for serious toxicity;pictures of mushrooms can be shown.
How long after ingestion did the
symptoms begin?
Symptoms that develop later than six hours after ingestion
are often associated with potentially lethal mushroom
toxins (exceptions are possible).
How much was eaten? Information about the amount may be useful in predictingthe course and degree of poisoning.
Were the mushrooms eaten at
more than one meal?
Symptoms may be the result of an earlier rather than the
most recent ingestion.
Were the mushrooms
cooked/boiled?
Duration and type of mushroom
storage?
Most mushroom poisonings are caused by edible
mushrooms and are due to incorrect processing after
harvesting, e.g., long-term storage of mushroom dishes,
mushroom storage in plastic bags.
Is everyone who ate the
mushrooms ill? Is anyone who did
not eat the mushrooms ill?
Help differentiate mushroom poisoning from other types
of food poisoning.
Were the mushrooms ingested for
recreational purposes?
Was any ethanol co-ingested?
Certain mushroom species (e.g., Coprinus) can cause a
disulfiram-like reaction when ethanol is ingested up to
48–72 h after consumption.
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Questions/Measures Comments
Physical examination
Classification of poisoning based upon clinical
presentation (e.g., gastroenteritis, liver failure, seizures,
cholinergic poisoning, hallucinations, renal failure) helpful
in guiding further treatment
Asservation of
mushrooms for analysis
Whenever possible, samples of all
ingested mushrooms should be
obtained for potential
identification by a trained
mycologist. Asservation of
remainders of dishes, fresh
mushrooms, peeling and waste.
Whole mushrooms are preferred, but identification can be
made on parts of the mushroom, especially the cap.
Further storage is facilitated by wrapping the mushrooms
in wax paper, placing it in a paper bag, and refrigerating
the sample. Storage in plastic bags should be avoided.
Contact with local poison
control centre/mycologist
Consultation with a medical
toxicologist/ mycologist is
advised to determine likely
species ingested based on clinical
findings, identification of
mushrooms, and specific
treatment.
For Switzerland: www.toxinfo.ch, www.vapko.ch
Laboratory
Complete blood count,
prothrombin time (PT), partial
thromboplastin time (PTT),
electrolytes, calcium, phosphate,
urea nitrogen, creatinine, creatine
kinase, liver enzymes, albumin,
cholestatic parameters
Additionally in symptomatic patients:
- Hepatic failure: blood gas analysis, glucose, lactate,
ammonia, lactate dehydrogenase (LDH)
- Altered mental status: blood gas analysis, glucose
- Cyanosis not responsive to oxygen:
methaemoglobin level
- Hypoxia: blood gas analysis
Therapy
Emergency and supportive
measures:
- Intravenous hydration,
antiemetic therapy
- Monitor for 12–24 h for
delayed onset symptoms
- If mushroom potentially
toxic: decontamination with
activated charcoal
Specific drugs and antidotes:Seizures:
- Seizures: benzodiazepines, pyridoxine
- Methemoglobinaemia: methylene blue
- Cholinergic syndrome: atropine
- Amatoxin-containing mushrooms: silibinin,
N-acetylcysteine, liver transplant in case of
fulminant hepatic failure
Other
If amatoxin-poisoning suspected:
identification and hospitalisation
of the table companions
(even if asymptomatic)
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